Literature DB >> 21857118

Genome-based versus gene-based theory of cancer: possible implications for clinical practice.

Natasa Todorovic-Rakovic1.   

Abstract

The current state in oncology research indicates that the attempts to explain such complex process as cancerogenesis by a single or several genetic mutations were not successful enough. On the other hand, chromosomal/genomic instability--almost universal features of malignant tumours which influence a global pattern of gene expression and, subsequently, many oncogenic pathways--were often disregarded and considered nonessential to clinical application. However, a new arising field of system biology including 'new forms' of genome diversity such as copy number variations (CNV) and high-throughput oncogene mutation profiling now reveal all the complexity of cancer and provide the final explanation of the oncogenic pathways, based on stochastic (onco)genomic variation rather than on (onco)genic concepts.

Entities:  

Mesh:

Year:  2011        PMID: 21857118     DOI: 10.1007/s12038-011-9099-9

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  59 in total

Review 1.  Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.

Authors:  D H Roukos
Journal:  Pharmacogenomics J       Date:  2010-10-26       Impact factor: 3.550

2.  Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

Authors:  Sanja Dacic; Melina Flanagan; Kathleen Cieply; Suresh Ramalingam; James Luketich; Chandra Belani; Samuel A Yousem
Journal:  Am J Clin Pathol       Date:  2006-06       Impact factor: 2.493

3.  Abnormal chromosome 8 copy number in cytological smears from breast carcinomas detected by means of fluorescence in situ hybridization (FISH).

Authors:  A M Bofin; B Ytterhus; H E Fjøsne; B M Hagmar
Journal:  Cytopathology       Date:  2003-02       Impact factor: 2.073

Review 4.  Recurrent chromosome aberrations in cancer.

Authors:  F Mitelman
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

5.  AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Authors:  Robert W Wilkinson; Rajesh Odedra; Simon P Heaton; Stephen R Wedge; Nicholas J Keen; Claire Crafter; John R Foster; Madeleine C Brady; Alison Bigley; Elaine Brown; Kate F Byth; Nigel C Barrass; Kirsten E Mundt; Kevin M Foote; Nicola M Heron; Frederic H Jung; Andrew A Mortlock; F Thomas Boyle; Stephen Green
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

6.  Chromosome 8 numerical aberrations in stage II invasive ductal carcinoma: correlation with patient outcome and poor prognosis.

Authors:  Yutaka Tagawa; Toru Yasutake; Yasushi Ikuta; Tadayuki Oka; Ryusuke Terada
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 7.  Aneuploidy and cancer.

Authors:  Harith Rajagopalan; Christoph Lengauer
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

8.  Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy.

Authors:  R Li; A Sonik; R Stindl; D Rasnick; P Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

9.  Exploiting the promiscuity of imatinib.

Authors:  Shun J Lee; Jean Y J Wang
Journal:  J Biol       Date:  2009-04-15

10.  Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.

Authors:  Marta Salido; Ignasi Tusquets; Josep M Corominas; Marta Suarez; Blanca Espinet; Cristina Corzo; Meritxell Bellet; Xavier Fabregat; Sergi Serrano; Francesc Solé
Journal:  Breast Cancer Res       Date:  2005-01-26       Impact factor: 6.466

View more
  1 in total

1.  Full Karyotype Interphase Cell Analysis.

Authors:  Adi Baumgartner; Christy Ferlatte Hartshorne; Aris A Polyzos; Heinz-Ulrich G Weier; Jingly Fung Weier; Ben O'Brien
Journal:  J Histochem Cytochem       Date:  2018-04-19       Impact factor: 2.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.